higher 28-day mortality rates than non-cancer patients (28.6% vs. 12.8%). While 28-day mortality rates of cancer patients decreased by 31%, clinical severity scores remained unchanged. After adjusting for confounders, there was an annual 6% decrease in the odds of dying at both 28-days and 1-year among cancer patients.
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Background
Cancer is a global public health concern and the second leading cause of death in the United
States and most developed countries [3] . Despite a slight decrease in cancer incidence over the last two decades, cancer prevalence continues to increase due to improved treatment and earlier diagnosis [4] .
Historically, advanced or end-stage oncological and hematological patients were, due to their limited prognosis, frequently not referred to intensive care units. Novel and more efficient antineoplastic treatments have resulted in prolonged progression-free and overall survival of oncological and hemato-oncological patients [3] . Consequently, a growing number of cancer patients is at risk of admission to intensive care units [1] .
Concurrently, the average prognosis of oncological patients remains less than that of the general population, thereby frequently resulting in controversy whether an ICU admission is an appropriate medical choice [1] . While several studies have described the characteristics of oncological patients admitted to ICU, only two studies have investigated trends in hematological and oncological ICU admissions in the UK [5] and hematological patients in the Netherlands [6] .
In both settings, the absolute number of oncologic patients admitted to intensive care units has increased. In the Netherlands, the odds of admission increased by an annualized 6% between 2004 and 2012, while the proportion of oncological patients admitted to British ICUs remained almost unchanged between 1997 and 2013. Of note, the Acute Physiology and Chronic Health Evaluation (APACHE-II) score for hematological patients at admission were the same in the Dutch and British cohorts (24 points). At the same time, both hospital (47% vs. 54%) and ICU mortality (34% vs. 41%) were approximately 7 percentage-points lower in the Dutch ICU cohort compared to the UK cohort, possibly indicating differences in referral pattern, aggressiveness of treatment or other patient characteristics. In both cohorts, hospital and ICU mortality for Regardless, the average prognosis of oncological patients remains less than that of the general population. For instance, hematological patients in the Netherlands had twice as high ICU mortality rates than patients without malignancy (34% vs. 17%). While prior studies have described oncological patient characteristics and outcomes in the U.S. [7] , no published longitudinal analysis for trends in ICU mortality for the US is available. In the following, we therefore aim to describe trends in admission numbers and patient characteristics for cancer patients admitted to the ICU. Furthermore, we aim to establish if 28-day and 1-year mortality changed over the 10-year period, after adjusting for covariates.
Methods
Patient information was extracted from a de-identified version of the MIMIC-III (v1.4) database using PostgreSQL (The PostgreSQL Global Development Group, https://www.postgresql.org). Previously established code from the MIMIC Code Repository was used to generate comorbidity scores and risk scores [8] .
MIMIC
A waiver of consent that has previously been obtained from the Institutional Review Boards of BIDMC and MIT is applicable to these datasets.
Cohort Selection
All adult patients aged 18 years or older with a diagnosis of any cancer type as identified by ICD-9 codes 140-199 (solid malignancies) and 209.0-3 (neuroendocrine carcinomas) or 200-208 (hematological malignancy) were included in this study. Patients with incomplete data on admission year, length of stay or severity of illness were excluded during data analysis. Since no complete annual data for 2001 and 2012 was available, all patients admitted in this period were excluded from the base population. If patients were admitted multiple times to the ICU, only their first admission was used for this analysis.
Covariates
Patient data on the following variables were extracted from the database:
Age at admission, gender, race, Elixhauser Comorbidity Index scores [9] , vasopressor duration, ventilation duration, OASIS scores [10] , SOFA scores [11] , APACHE-III scores [12] , renal replacement therapy, do not resuscitate order (DNR) at admission, ICU mortality, mortality (from the Social Security death records). SOFA scores were interpreted as being low (0-5), medium (6-10) and high risk (≥11 points), respectively. Duration of ventilation and duration of vasopressor use were converted from continuous to binary variables. Race was categorized into a white and non-white category.
Cancer diagnoses were clustered according to ICD-9 codes into: Oral malignancies (1400- 
Outcomes
The primary study outcomes were (a) trends in the number and relative frequency of oncological patients admitted to the ICU and (b) all-cause mortality within 28 days and 1 year after ICU admission. Secondary outcomes were (a) hospital and ICU length of stay, (b) changes in clinical severity scores and (c) predictors of mortality.
Statistical Analysis
All analyses were performed using the open-access software R (version 3.4.2, http://www.Rproject.org/) and the following packages: tableone, ggplot2, dplyr, MIMICbook, epitools, sjplot, MASS. For table 1, chi-square testing was performed for categorical variables (with continuity correction) and one-way ANOVA for parametric continuous variables. Multiple logistic regression was used to adjust for covariate levels in the longitudinal trend analysis for 28-day including the most important confounders (C.M.S.& L.A.C.). An alpha-level of 0.05 was used as the cutoff value to reject the null hypotheses. Collinearity analyses were performed, hence only APACHE-III scores were included in the final model. We checked the final model for interaction terms, however did not find any interaction terms that were statistically significant after Bonferroni adjustment.
Reproducibility
Both the code for the SQL queries and data analysis will be made freely publicly available after acceptance of this article for publication. Due to privacy concerns, the re-identified data on year of admission will not be made publicly available.
Results
By restricting our analysis to the first ICU stay for each patient, a total unique patient cohort of 41,468 ICU admissions was obtained. Of these, 3953 had an oncologic malignancy, 1100 had a hematological malignancy and 49 patients had a diagnosis of both a hematological and solid malignancy ( fig. 1 ).
Baseline patient characteristics differed considerably between all subgroups (table 1).
Hematological patients had highest mean clinical severity scores and a higher rate of DNR orders on admission (p<0.001), however were less likely to be ventilated or to receive vasopressors (p<0.001). Furthermore, mean length of ICU and hospital stay for hematological patients was significantly longer than that of non-cancer patients (p<0.001). Oncological patients had patient characteristics that were more similar to those of non-cancer patient, having comparable clinical severity scores and only slightly longer length of ICU and hospital stays. Of note, oncological patients less frequently received vasopressin and ventilation.
Between 2002 and 2011, the overall number of patients admitted to the ICU increased from 3110 to 5076. Over the same period, the number of patients with cancer more than double from 285 to 678 (Suppl. table 1) and 28-day mortality of cancer patients decreased from 36.1% in carcinomas) and cancer of the lip, oral cavity and pharynx having the highest mortality rate.
Genitourinary and connective tissue (including breast) cancers had the lowest mortality rates of all malignancies. Mortality rates were closely associated with clinical severity scores across all cancer subtypes. Of note, patients with high SOFA-scores (≥11) and a connective tissue malignancy (including breast cancer, N=2) or genitourinary cancer (N=7) had a 100% probability of dying at 28-days. Similarly, patients with gastrointestinal cancer (N=49) or leukemia (N=23) and high SOFA-scores (≥11) had a close to 100% probability of dying within 1-year of ICU admission (Supp. Fig. 1 ).
Multivariate logistic regression analysis confirmed the observed trends in mortality. For the whole ICU cohort, a do-not-resuscitate order at admission, any type of cancer and year of admission were the strongest predictors of both 28-day and 1-year mortality rates after adjustment for covariates (suppl. fig. 2 ). A DNR order was associated with a 3.69-times higher odds (95%CI: 3.30, 4.13) of death within 28 days of admission, and a malignancy with a 2.62 
Discussion
This is one of the largest studies investigating trends in patient characteristics and outcomes of oncological patients admitted to the ICU worldwide, and the first study from the U.S. More than 58,000 ICU admissions were analyzed and 41,468 patients were included in the final analysis, among which were 1100 hematological and 3953 oncological patients. Cancer patients had comparable clinical severity scores compared to non-cancer patients, yet were more likely to die within 28 days (RR=2.23) and within 1 year (RR=2.58). Mortality rates decreased significantly over the study period (-7% annual decrease) for all patients, with cancer patients having a bigger decrease in mortality rates than non-cancer patients.
Our findings confirm the previously reported decrease in mortality rates observed in the UK [5] and the Netherlands [13] Clinicians are frequently faced with the difficult decision whether patients with serious chronic conditions that limit their life expectancy should be admitted to the intensive care unit. This is particularly challenging for oncological patients, where long-term survival might more depend on their underlying malignancy than their acute health problem. Our findings together with previously published results [14, 16, 19, 20] suggests that elderly patients with high clinical severity scores, multiple comorbidities and certain cancer types do not sustain long-term survival regardless of intensive treatment. Concurrently, the presence of any malignancy alone is an insufficient predictor of both 28-day and 1-year mortality and treatment decisions should not be based on oncological prognosis alone.
Analysis of over 40,000 admitted patients, including more than 5,000 (hemato-)oncological patients allowed for precise and stratified analysis of patient characteristics, outcomes and predictive factors. Data was retrieved from clinical databases that were compiled at the time of treatment, thereby minimizing bias that may occur due to the retrospective study design. The high resolution of the clinical data is another advantage of this study. Furthermore, we had sufficient statistical power to detect annual changes in mortality of cancer patients. [7] . Interestingly, 28-day mortality for both cancer and non-cancer patients decreased approx. equally on the multiplicative scale (-6% annually). At the same time, the absolute improvement in survival is larger for cancer patients, due to an approx. three times higher mortality rate at baseline.
In this descriptive study, which should not be interpreted as a prognostic survival model, we Elixhauser and Apache-III scores were singificantly associated with both 28-day and 1 year mortality, e.g. a 1 point increase in APACHE-III increasing the odds of dying within 28 days by 4%. Admission to a ICU other than the medical was associated with increased survival. (B) Notable differences between 28-day and 1-year survival are the weaker association between both vasopressor use and ventialtion with survival and a signficant assoication between white race and survival.
Legend to the tables 
Supplementary material
Supplementary table 1: trends in cancer patient admission, characteristics and outcomes by year of admission. The number of oncological cases admitted to the ICU increased by 238% over the 10-year period. Clinical severity scores remained approximately unchanged, while use of vasopressors and ventilation decreased significantly. The mean Elixhauser comorbidity score increase steadily over the study period. Both 28-day and 1-year mortality decreased over time, with the 28-day mortality (-31%) decreasing faster than 1-year mortality (-18%).
Supplementary figure 1: (A) 28-days and (B)
1-year mortality rates by cancer type and SOFA-scores. SOFA scores were strongly associated with mortality across all cancer subtypes. Overall, cancer patients had worse outcomes compared to non-cancer patients with similar SOFA scores. Patients with high SOFA-scores (≥11) and a connective tissue malignancy (including breast cancer, N=2) and genitourinary cancer (N=7) had a 100% probability of dying at 28-days. Similarly, patients with gastrointestinal cancer (N=49) and leukemia (N=23) and high SOFA-scores (≥11) had a close to 100% probability of dying at 1-year.
Supplementary figure 2: Results of the multivariate model for (A) 28-day and (B) 1-year mortality for the whole cohort. (A)
After adjusting for other covariates, DNR at admission (OR=3.69) was the strongest predictor of 28-day mortality, followed by any use of mechanical ventilation and presence of any malignancy. Year of admission was a strong protective factor, with mortality rates decreaseing by 6% every year. With each year increase in age at admission, the odds of dying within 28 days and 1 year increased by 2%. A one point increase in APACHE-III scores was closer asscoiated with a higher increase in the odds of dying within 28 days (4%) than 1 year (2%). 
